Physician profile
Anthony J Tickner
NPI 1790872497
$283,938.36
in general payments reported to CMS, 2019-2025
21 companies · $13K in 2025
The $13K reported for 2025 was more than what 98% of Primary Podiatric Medicine providers received nationally (typical 2025 total: $232).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $36K · 2021: $13K · 2022: $40K · 2023: $43K · 2024: $105K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $81K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $43K · Consulting Fee: $15K · Travel and Lodging: $9,033 · Honoraria: $5,100 · Food and Beverage: $4,135 · Education: $2,700 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $81,200.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $42,825.00 |
| Consulting Fee | $15,145.00 |
| Travel and Lodging | $9,033.27 |
| Honoraria | $5,100.00 |
| Food and Beverage | $4,134.86 |
| Education | $2,700.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $450.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $121,877.24 | 2019-2025 | |
| Kerecis Limited | $86,469.54 | 2019-2025 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Integra Lifesciences Corporation | $50,339.32 | 2019-2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Triad Life Sciences INC. | $9,163.47 | 2022 | |
| Urgo Medical North America, LLC | $7,060.00 | 2019-2020 | |
| Musculoskeletal Transplant Foundation INC. | $4,530.60 | 2020-2022 | |
| Kairos Surgical INC | $1,215.14 | 2021 | |
| Treace Medical Concepts, INC. | $843.82 | 2022 | |
| Reapplix INC. | $538.68 | 2022-2025 | 3c Patch Kit - Box |
| Organogenesis INC. | $306.56 | 2019-2023 | Puraply |
| Medela LLC | $296.65 | 2019-2020 | |
| Smith+Nephew, INC. | $287.34 | 2019-2023 | Collagenase Santyl, Regranex |
| Aroa Biosurgery Incorporated | $246.34 | 2019-2020 | |
| Hydrofera LLC | $224.94 | 2022-2023 | Hydrofera Blue, Cutimed Sorbact |
| Avita Medical Americas, LLC | $164.85 | 2025 | Recell, Permeaderm, Cohealyx |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Misonix INC | $132.08 | 2019-2021 | |
| Abbvie INC. | $87.74 | 2023 | Dalvance |
| Stryker Corporation | $80.67 | 2021-2022 | |
| Tei Medical INC. | $27.50 | 2019 | |
| Zimmer Biomet Holdings, INC. | $26.52 | 2023 | Cannulated Screws |
| Bioventus LLC | $19.36 | 2023 | Sonicone Clinic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Tickner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.